Hepatocyte cell therapy in liver disease

David Christopher Bartlett, Philip N Newsome

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)


Liver disease is a leading cause of morbidity and mortality. Liver transplantation remains the only proven treatment for end-stage liver failure but is limited by the availability of donor organs. Hepatocyte cell therapy, either with bioartificial liver devices or hepatocyte transplantation, may help address this by delaying or preventing liver transplantation. Early clinical studies have shown promising results, however in most cases, the benefit has been short lived and so further research into these therapies is required. Alternative sources of hepatocytes, including stem cell-derived hepatocytes, are being investigated as the isolation of primary human hepatocytes is limited by the same shortage of donor organs. This review summarises the current clinical experience of hepatocyte cell therapy together with an overview of possible alternative sources of hepatocytes. Current and future areas for research that might lead towards the realisation of the full potential of hepatocyte cell therapy are discussed.

Original languageEnglish
Pages (from-to)1261-72
Number of pages12
JournalExpert review of gastroenterology & hepatology
Issue number10
Publication statusPublished - Oct 2015


Dive into the research topics of 'Hepatocyte cell therapy in liver disease'. Together they form a unique fingerprint.

Cite this